GSK Bio
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
GlaxoSmithKline’s Trelegy Ellipta won regulatory approval for the treatment of asthma in patients aged 18 years and older. Here’s what you need to learn.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.
Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
In a regulatory filing with the U.S. Securities and Exchange Commission, Translate Bio indicated that the COVID-19 vaccine it is developing with Sanofi induced an immune response in non-human studies.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.
JOBS
IN THE PRESS